TrialPanorama/Dataset huggingface dataset:
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Product Evaluation for the Effectiveness of the ClearGuard™ HD End Cap
Brief Summary: To assess positive blood cultures (PBCs) in hemodialysis central venous catheter (CVC) patients using two FDA cleared devices: ClearGuard HD end caps compared to conventional end caps.


Options:
A: Inclusion Criteria:

* All patients dialyzing with a central venous catheter

Exclusion Criteria:

* Known allergy to chlorhexidine
B: Inclusion Criteria:

* Patients of both genders, over 18 years,
* Chronic hemodialysis 3 times a week, with two tunnel silicone catheters since at least 15 days,
* Written informed consent
* Social security

Exclusion Criteria:

* Antibiotic therapy during selection phase,
* Partial or complete catheter occlusion during selection phase,
* Venous pressure at dialysis connection \> 300 mmHg,
* Known allergy to ethanol,
* Patient involved in any other clinical trial or in the exclusion period
* Severe co-morbidity
* Acute or chronic infectious disease
* Evolutive neoplasia,
* HIV, HCV positive serology at inclusion,
* Scheduled surgery
C: Inclusion Criteria:

* Any adult (≥ 18 years of age) who has ESRD and a prevalent or incident tunneled hemodialysis catheter and expected to continue hemodialysis for 3 months will be eligible for enrollment.

Exclusion Criteria:

* The following patients will be excluded from study entry:

  1. patient is unable (and no guardian or legal representative is available) or unwilling to provide informed consent and
  2. patient is allergic to NAC, tigecycline, minocycline, or heparin.

The following patients will be excluded from randomization:

1. patient has evidence of a complicated bacteremia such as endocarditis, septic thrombophlebitis, septic emboli, osteomyelitis, deep seated abscess, or hypotension requiring use of vasopressors,
2. patient has evidence of an exit site infection around the catheter such as a pus pocket, purulent drainage, or erythema,
3. patient is pregnant or will become pregnant,
4. the infection is due to an organism that is resistant to tigecycline such as Candida or Pseudomonas species.
D: Inclusion Criteria:

* All patients end stage renal disease on hemodialysis from tunneled cuffed dialysis catheters with suspected catheter-related bloodstream infection with no identifiable infection source except the catheter were included.

Exclusion Criteria:

* metastatic infection,

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Acceptability and Feasibility of Micronutrient Powders Versus Iron Syrup for Anemia Prevention in Young Children
Brief Summary: This study seeks to assess the acceptability, compliance, and preference for iron supplementation; micronutrient powders (MNP) versus iron syrup. Additionally, this study seeks to assess front line health worker perceptions and experiences regarding ease of implementation of each strategy and delivery strategy preference.


Options:
A: Inclusion Criteria:

* Age 6-36 months at the time of enrollment
* Live within the study area for the duration of the intervention and follow-up period

Exclusion Criteria:

* Unavailable for enrollment on 3 separate household visits
* Parental refusal to give informed consent
B: Inclusion Criteria:

* Singleton Children or one child per home

Exclusion Criteria:

* Currently taking iron supplements
* Mid upper arm circumference (MUAC) or less than 11.5 cm
* Suspected severe anemia
* Known case of haemoglobinopathy
* History of repeated blood transfusion
* Current pneumonia
* Current fever
* Acute diarrhea
C: Inclusion Criteria:

* Guatemala: pregnant mothers and subsequently their born children up to the age of 24 months;
* Burundi: cross-sectional study: children 0 to 42 of age.

Exclusion Criteria:

* none
D: Inclusion Criteria:

* 6 to 59 months of age
* Not malnourished or moderately acutely malnourished children
* Diagnosis of malaria and/or diarrhoea and/or LRTI
* Intending to remain in area for the duration of the 6 month follow-up
* Living within approximately 60 minutes walking distance from the clinic
* Informed consent from a guardian\*

Exclusion Criteria:

* Child is exclusively breastfeeding
* Child is severely malnourished
* Presence of 'General Danger Signs'
* Presence of severe disease (including severe malaria, severe LRTI, severe diarrhoea)
* Needing hospitalisation for any reason
* Known history of allergy to the nutritional supplementation
* Having a sibling enrolled in the study\*

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: The Effect of Replacement of Vitamin K Antagonist by Rivaroxaban With or Without Vitamin K2 Supplementation on Vascular Calcifications in Chronic Hemodialysis Patients: A Randomized Controlled Trial
Brief Summary: This study examines patients on chronic hemodialysis with non-valvular atrial fibrillation, who have a CHA2DS2-VASc Score of ≥ 2 and therefore are candidates for or already receive a vitamin K antagonist.

The first question is whether replacement of the vitamin K antagonist by rivaroxaban is able to slow progression of vascular calcification. The second question is whether addition of vitamin K2 to rivaroxaban can further slow down or even halt the progression of vascular calcification.


Options:
A: Inclusion Criteria:

1. hemodialysis patients with age \> 18 years on regular bicarbonate hemodialysis or hemodiafiltration treatment three times a week;
2. clinical stability at least three months before the study started;

Exclusion Criteria:

1. active gastrointestinal bleeding (one ore more positive hemoccult test in the last 8 weeks, melena or proctoraggia in the last 6 months )
2. hemorrhagic stroke
3. Myeloproliferative disorders
4. Hereditary deficiency of coagulation factors, LAC phenomenon or antiphospholipid syndrome
5. Malignant disease
6. Patient submitted to antithrombotic prophylaxis with LMWH
7. Immunosuppressive therapy
8. Participation in other clinical trials
B: Inclusion Criteria:

* platelet below 10k PTT above 60 second INR above 20 patient with bleeding (epistaxis, orbital bleeding, hematuria) recent brain hemorrhage (within 6 months) receiving anticoagulant therapy (coumadin or NOAC) dual antiplatelet agent users received major surgery within one month

Exclusion Criteria:

* cancer liver cirrhosis pregnancy drug allergy current bleeding on major organ (brain, gastrointestinal)
C: Inclusion Criteria:

* end stage renal failure treated with chronic hemodialysis
* atrial fibrillation
* CHA2DS2-VASc Score ≥ 2
* ability to provide informed consent

Exclusion Criteria:

* known intestinal malabsorption or inability to take oral medication
* inability to stop co-medication that causes major interactions with rivaroxaban (e.g. ketoconazole, itraconazole, voriconazole, posaconazole, ritonavir, rifampicin, phenytoin, carbamazepine, phenobarbital or St John's wort)
* investigator's assessment that the subject's life expectancy is less than 1 year
* prosthetic mechanical heart valve
* contraindication for anticoagulation
* liver dysfunction Child-Pugh grade B-C
* pregnancy, breastfeeding, inadequate contraception
* incompliance with medication and scheduled investigations
D: Inclusion Criteria:

* Any permanent catheter inserted intravenous either femoral or jugular either for hemodialysis, replacement or chemotherapy.

Exclusion Criteria:

* History of central venous occlusion, contraindication of direct oral anticoagulants.

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Effect on Attendance if Including Focused Information of Spirometry in Preventive Health Checks - a Randomized Controlled Trial in Primary Health Care
Brief Summary: The purpose of this study is to investigate if focused information of spirometry in the invitation to preventive health checks will increase the attendance compared with a standard invitation to preventive health checks.


Options:
A: Inclusion Criteria:

Screening study: Every one aged 40-69 years (UK and DK) or 50-69 years(NL). Treatment study: All with screen detected type 2 diabetes.

Exclusion Criteria:

Participants are excluded if they already have diabetes at time of screening, are pregnant or lactating or have a severe psychotic illness, are house bound or have an illness with a likely survival of less than one year.
B: Inclusion Criteria:

* men aged 65-74 years old living in the central region of Denmark

Exclusion Criteria:

* men not aged 65-74 years
* men aged 65-74 years old not living in the central region of Denmark
C: Inclusion Criteria:

* Citizens in the municipality of Randers per 01.01.2012
* Randomized for the fourth group of five groups in total to be invited for a preventive health check as part of the health promotion program, Check your health prevention program, conducted in the years 2012 to 2017.

Exclusion Criteria:

* Terminal illness as reported by the citizens general practitioner.
D: Inclusion Criteria:Potential participants must be either parents, children or brothers and sisters of the affected person (individual with documented history of CHD).

More than 18 years of age.

-

Exclusion Criteria:

Bedridden and terminally ill patients. Those who are not willing to provide written informed consent will be also excluded.

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Postprandial Effect of Breakfast Glycemic Index on Vascular Function, Insulinemia and Cognitive Performance, a Crossover Clinical Trial (BGI Study)
Brief Summary: This is a crossover clinical trial aimed at adults (aged 20-40 years, with no cardiovascular disease), selected by consecutive sampling at urban primary care health clinics in Salamanca (Spain). Each subject will complete three interventions, with a washout period of one week: control breakfast (water), low glycemic index breakfast (apple, yogurt, walnuts and black chocolate) and high glycemic index breakfast (grape juice, bread and strawberry jam). The postprandial effect will be assessed at 60 and 120 minutes from each breakfast, measuring blood glucose and insulin and cognitive performance. Measurements will be performed of central blood pressure, augmentation index, pulse wave velocity, cardiac output and total peripheral vascular resistance at minutes (-10, 0, +15, +30, +45, +60, +75, +90, +105 and +120).


Options:
A: Inclusion Criteria:

* male, age 35-60 years, healthy
* female, age 35-60 years, healthy

Exclusion Criteria:

* diabetes mellitus, acute inflammation, arrhythmia, active malignancy, terminal renal failure, signs, symptoms or medication indicative of manifest cardiovascular disease (CAD, PAD, CVD)
B: Inclusion Criteria:

* age 25-65 years
* resting systolic pressure 140-159 mmHg or diastolic blood pressure 90-99 mmHg
* BMI 25.0- 29.9

Exclusion Criteria:

* smoking
* regular medication for hypertension, cardiovascular disease, diabetes or asthma
C: Inclusion Criteria:

* Young adults.
* Aged between 20 and 40 years.
* Both sexes.
* Those agree to sign the informed consent.

Exclusion Criteria:

* History of cardiovascular events (acute myocardial infarction, stroke, etc.).
* History of hypertension, diabetes mellitus or dyslipidemia.
* Pharmacological treatment for any of the above conditions.
* Diagnosis of clinically demonstrable neurological and/or neuropsychological disease.
* Excessive consumption of toxic substances.
* Celiac patients and/or those intolerant to lactose.
* Subjects on a low-calorie and/or low-sodium diet.
* Pregnant women.
* Those with any other circumstance that the investigators consider could interfere with the study procedures.
D: Inclusion Criteria:

* CAD patients over 18 years of age
* Contact university for more details.

Exclusion Criteria:

* Contact university for more details.

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Comparison of the Prophylactic Anti-emetic Efficacy of Gabapentin and Ramosetron in Patients Undergoing Laparoscopic Gynecological Surgery
Brief Summary: This study was designed to compare the effects of gabapentin and ramosetron on PONV in patients undergoing laparoscopic gynecologic surgery.


Options:
A: Inclusion Criteria:

* Patients with ASA physical status 1 and 2 between 20 and 65 years undergoing laparoscopic gynecological surgery with patient-controlled analgesia for postoperative pain control.

Exclusion Criteria:

* Pregnant women
* Patients who took sedatives, antiemetics, hypnotics, analgesics, steroid, or gabapentin
* Patients with neurological deficits
* Patients with history of drug abuse and allergy of study drugs
B: Inclusion Criteria:

* Arthroscopic subacromial decompression and/or acromioclavicular resection
* General anaesthesia
* Daysurgery, Horsens Hospital

Exclusion Criteria:

* Incompetent
* Pregnant
* Age under 18 or over 90 years
* Allergy toward dexamethasone
* Diabetes
* Active gastric ulcer
* Untreated hypertension
* Glaucoma
* Daily use of glucocorticoids or strong opioids
* Daily use of analgesics for unrelated illness
* Myasthenia gravis
* Mitochondrial disorders
C: Inclusion Criteria:

* Patients over or equal to the age of 18 years old who can understand the study protocol and are able to give consent
* Patients with an American Society of Anaesthesiology (ASA) classification 1 to 3
* Patients must have a preoperative oral 24 hour opioid consumption of less than or equal to 30 mg morphine equivalents
* Patients must be able to understand and be able to use patient controlled analgesia
* Patients must be undergoing a primary total knee arthroplasty with neuraxial anesthesia

Exclusion Criteria:

* Patients with a contraindication to neuraxial and/or regional anaesthesia
* Patients with an allergy to local anaesthetics
* Patients who have chronic pain not related to their knee joint
* Patients with chronic opioid use (daily or almost daily use \>3 months)
* Patients with contraindications to dexamethasone (allergy, infection, Insulin dependent Diabetes Mellitus)
* Patients with pre-existing neuropathy
* Patients with hepatic failure
* Patients with renal failure with eGFR\<60
* Patients with allergy to ketorolac or NSAIDs
D: Inclusion Criteria:

* American Society of Anesthesiologists (ASA) physical status I or II
* aged between 18 to 60yr
* scheduled for elective gynecological laparoscopic surgery requiring general anesthesia

Exclusion Criteria:

* pregnancy or breastfeeding
* mental retardation
* psychiatric or neurological disease
* use of antiemetics, emetogenic drugs, opioids or glucocorticosteroids within 3 days prior to surgery
* known allergy to tropisetron or dexamethasone
* nausea and/or vomiting within 24 hr prior to surgery
* implantation of a cardiac pacemaker, cardioverter, or defibrillator
* any skin problem at the acupoint stimulation area

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: N/A
Brief Summary: The aims of this study were to compare health related quality of life, comforts degrees，retention effectiveness, and failure rates as well as survival times between two clear overlay retainers with different thicknesses, thus to provide basis information regarding appropriate selections of the thickness of clear overlay retainers.


Options:
A: 1. Inclusion criteria

   1. fixed appliance treatment following both arches;
   2. indicated for vacuum formed thermoplastic retainers as retention phase in treatment plan;
2. Exclusion criteria:

   1. single-arch or sectional fixed appliance treatment,
   2. hypodontia requiring tooth replacement on the retainer as a temporary measure,
   3. undergone rapid maxillary expansion,
   4. indicated for double retention regime (bonded retainers),
   5. early debonding patients.
   6. patients intending to relocate within the study period
   7. patient with learning difficulties and can't read written instructions/questionnaire in English or Malay
   8. patient with cleft lip or palate
   9. has undergone surgical treatment
B: Inclusion Criteria:

* patients that have completed orthodontic treatment (are at stage of debonding) with fixed appliances in the upper and lower arch
* age 12- 18

Exclusion Criteria:

* systematic diseases
* craniofacial anomalies (clefts, etc)
* handicapped patients with problems of compliance
* pregnant women
* previous orthodontic treatment or compromise orthodontic treatment
C: Inclusion Criteria:

* Patients after active orthodontic treatment;
* Must be healthy without systemic and oral diseases;
* The central incisors, canines and first molars of both upper and lower arches must be existed;
* Agreed to the trial and signed informed consent forms, either by themselves, or their parents.

Exclusion Criteria:

* Oral habits such as bruxism and clenching,
* Do not accept this type of retainers
D: Inclusion Criteria:

* Subjects who have completed fixed appliance orthodontic treatment.
* Subjects who have signed the consent forms.
* Subjects who have accepted the terms and conditions of visiting after every three months for one year.
* Non extraction cases in the mandibular arch with no IPR.
* Patients without caries/ restoration/ fracture on the lower anterior teeth.
* Patients with healthy periodontium with no periodontal disease at that time.

Exclusion Criteria:

* Presence of syndrome or systemic disease.
* Patients taking medications/ drugs.
* Patients with poor oral hygiene.
* Patients with congenitally absent/ missing anterior teeth in the mandibular arch.
* Patients with habit of clenching/ bruxism.
* Patients with history of betel nut chewing.
* Presence of occlusal interferences.

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Intravenous Versus Combined Oral and Intravenous Antimicrobial Prophylaxis for the Prevention of Surgical Site Infection in Elective Colorectal Surgery: A Double-blinded Multicenter Prospective Randomized Controlled Trial
Brief Summary: To assess the effects of a combined antimicrobial prophylaxis using oral ornidazole (the day before surgery) and intravenous cephalosporin (before surgical incision) with that of intravenous cephalosporin alone (standard of care) in combination with oral placebo on the incidence of SSI within 30 days after elective colorectal surgery.


Options:
A: Inclusion Criteria:

* Patients undergoing ileocolic resections, partial and total colectomies, and rectal resections for neoplasm, inflammatory bowel disease, or diverticulitis
* Subjects with the mental capacity to give informed consent

Exclusion Criteria:

* Patients undergoing emergent colorectal resections
* Patients who are decisionally-impaired and lack the mental capacity to give informed consent
B: Inclusion Criteria:

* Age \> 18
* Laparoscopic or non-laparoscopic elective colorectal surgery

Exclusion Criteria:

* Non elective colorectal surgery (emergent surgery and/or reintervention or revision of a previous colorectal procedure)
* Significant concomitant surgical procedure (e.g., liver resection for metastasis)
* Bacterial infection at the time of surgery or antimicrobial therapy up to 2 weeks before surgery
* Inflammatory bowel disease
* Severe obesity (defined as a BMI \>35 kg/m2)
* Known history of hypersensitivity to β-lactams and imidazoles
* Preoperative severe impairment in renal function (creatinine clearance (MDRD) \< 30 ml/min)
* Patients with known colonization with multidrug-resistant digestive bacteria, especially multidrug-resistant gram-negative bacteria (requiring specific infection control measures)
* Allergy to lactose, galactose intolerance, Lapp lactase deficiency or glucose/galactose malabsorption (rare metabolic disease)
* Pregnant women, breastfeeding women, women of childbearing age without effective contraceptive- Refusal to participate or inability to provide informed consent
C: Inclusion Criteria:

* Have a planned of resection of rectum
* Have signed approved informed consent form for the study.

Exclusion Criteria:

* Significant simultaneous surgical procedure (e.g., liver resection of metastasis)
* Bacterial infection at the time of surgery or antimicrobial therapy up to 4 weeks before surgery
* Preoperative severe impairment in renal function (creatinine clearance (MDRD) \< 30 ml/min)
* Allergy on the study drugs .
D: Inclusion Criteria:

* Scheduled colorectal cancer surgery

Exclusion Criteria:

* Emergency surgery
* Obstructive and perforated cancer
* Intolerance to bowel preparation regimen
* Allergies to orally administered antibiotics

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Myocardial Ischemia and Transfusion: A Pilot, Multi-centre, Open-label Randomized Controlled Trial of Two Commonly Used Transfusion Strategies in Patients With Myocardial Infarction.
Brief Summary: MINT: A pilot, multi-centre, open-label randomized controlled trial of two commonly used transfusion strategies in patients with myocardial infarction.


Options:
A: Inclusion Criteria:

* Age 18 or older
* Planned cardiac surgery using cardiopulmonary bypass
* Informed consent obtained
* Preoperative European System for Cardiac Operative Risk Evaluation (EuroSCORE I) of 6 or more

Exclusion Criteria:

* Patients who are unable to receive or who refuse blood products
* Patients who are involved in a preoperative autologous pre-donation program
* Patients who are having a heart transplant or having surgery solely for an insertion of a ventricular assist device
* Pregnancy or lactation (a negative pregnancy test must be obtained prior to randomization for women of childbearing potential.)
* Patients who are unable to receive or who refuse blood products
B: Inclusion Criteria:

* Care Score of 3/4 or age \>/= 80
* Signed informed consent

Exclusion Criteria:

* Patients who refuse participation
* Unable to or refuse blood products
* Involved in an autologous pre-donation program
C: Inclusion Criteria:

* Hospitalized patients with hemoglobin level less than 100 g/L who present with an ST-segment Elevation Myocardial Infarction (STEMI), or Non-ST-Elevation Myocardial Infarction (NSTEMI);
* Rise in cardiac biomarker values with at least one value above the 99th percentile (preferably cardiac troponin cTn )
* Presence of one of the following:

  * symptoms of ischemia;
  * new/presumed new ST segment-T wave (ST-T) changes or new left bundle branch (LBBB);
  * development of pathological Q waves;
  * imaging evidence of new loss of viable myocardium or new regional wall motion abnormality;
  * identification of an intracoronary thrombus by angiography

Exclusion Criteria:

* Patients with uncontrolled acute bleeding at the time of randomization defined as the need for uncrossed or non-type specific blood;
* Patients who decline blood transfusion;
* Patients who have a planned cardiac surgery or immediate post-cardiac surgery;Patients who have been deemed palliative by their treatment team (no commitment to aggressive on-going care);
* If known that follow-up will not be possible at 30 days;
* Previous participation in the MINT Trial.
D: Inclusion Criteria:

* All elective primary and redo adult cardiac surgical patients for coronary artery bypass grafting, valve procedure or combined procedures
* Adults patients
* Written informed consent

Exclusion Criteria:

* Age less than 18 years
* Transplant procedures
* Emergency procedures
* Aortic repairs
* Congenital procedures
* Previous anemia (hemoglobin lower than 10 g/dL)
* Previous thrombocytopenia (platelet number lower than 100.000/mm3)
* Previous known coagulopathy
* Pregnancy
* Those unable to receive blood transfusion
* Patients who refused participation in the study

Answer: C